Nephrotoxicity Biomarker Prepares For Clinic After FDA Blesses Animal Test

The firms that obtained FDA/EMEA qualification of seven nephrotoxicity biomarkers for preclinical drug testing are midway through development of a protocol to test their efficacy in a clinical trial